» Articles » PMID: 28150122

Use of Non-conventional Medicine Two Years After Cancer Diagnosis in France: Evidence from the VICAN Survey

Overview
Journal J Cancer Surviv
Specialty Oncology
Date 2017 Feb 3
PMID 28150122
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The purpose of this study was to assess the use of non-conventional medicine (NCM) in a representative sample of French patients 2 years after cancer diagnosis.

Methods: The study was based on data obtained in the VICAN survey (2012) on a representative sample of 4349 patients 2 years after cancer diagnosis. Self-reported data were collected at telephone interviews with patients. The questionnaire addressed the various types of non-conventional treatments used at the time of the survey.

Results: Among the participants, 16.4% reported that they used NCM, and 45.3% of this group had not used NCM before cancer diagnosis (new NCM users). Commonly, NCMs used were homeopathy (64.0%), acupuncture (22.1%), osteopathy (15.1%), herbal medicine (8.1%), diets (7.3%) and energy therapies (5.8%). NCM use was found to be significantly associated with younger age, female gender and a higher education level. Previous NCM use was significantly associated with having a managerial occupation and an expected 5-year survival rate ≥80% at diagnosis; recent NCM use was associated with cancer progression since diagnosis, impaired quality of life and higher pain reports.

Conclusion: This is the first study on NCM use 2 years after cancer diagnosis in France. In nearly half of the NCM users, cancer diagnosis was one of the main factors which incited patients to use NCM. Apart from the NCM users' socioeconomic profile, the present results show that impaired health was a decisive factor: opting for unconventional approaches was therefore a pragmatic response to needs which conventional medicine fails to meet during the course of the disease.

Implications For Cancer Survivors: Better information of patients and caregivers is needed to allow access to these therapies to a larger population of survivors.

Citing Articles

Socio-demographic and health-related determinants of patients' overall rating and experiences of cancer care.

Arditi C, Eicher M, Junod J, Peytremann-Bridevaux I BMC Cancer. 2023; 23(1):918.

PMID: 37773108 PMC: 10540394. DOI: 10.1186/s12885-023-11445-6.


Prevalence of drug-drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management.

Bellesoeur A, Gataa I, Jouinot A, Mershati S, Piketty A, Tlemsani C Cancer Chemother Pharmacol. 2021; 88(4):741-751.

PMID: 34304283 DOI: 10.1007/s00280-021-04311-4.


Real-life drug-drug and herb-drug interactions in outpatients taking oral anticancer drugs: comparison with databases.

Prely H, Herledan C, Caffin A, Baudouin A, Larbre V, Maire M J Cancer Res Clin Oncol. 2021; 148(3):707-718.

PMID: 33914124 DOI: 10.1007/s00432-021-03645-z.


Integrative Oncology: An International Perspective from Six Countries.

Toledano A, Rao S, Frenkel M, Rossi E, Bagot J, Theunissen I Integr Cancer Ther. 2021; 20:15347354211004730.

PMID: 33784850 PMC: 8020040. DOI: 10.1177/15347354211004730.


Perceptions of homeopathy in supportive cancer care among oncologists and general practitioners in France.

Bagot J, Theunissen I, Serral A Support Care Cancer. 2021; 29(10):5873-5881.

PMID: 33763723 PMC: 8410724. DOI: 10.1007/s00520-021-06137-5.


References
1.
Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J . Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005; 114(1-2):29-36. DOI: 10.1016/j.pain.2004.12.010. View

2.
Portenoy R . Development and testing of a neuropathic pain screening questionnaire: ID Pain. Curr Med Res Opin. 2006; 22(8):1555-65. DOI: 10.1185/030079906X115702. View

3.
Montbriand M . Abandoning biomedicine for alternate therapies: oncology patients' stories. Cancer Nurs. 1998; 21(1):36-45. DOI: 10.1097/00002820-199802000-00005. View

4.
KELNER M, Wellman B . Health care and consumer choice: medical and alternative therapies. Soc Sci Med. 1997; 45(2):203-12. DOI: 10.1016/s0277-9536(96)00334-6. View

5.
Kersnik J . Predictive characteristics of users of alternative medicine. Schweiz Med Wochenschr. 2000; 130(11):390-4. View